Figure 2.
Mechanism of action of novel KRAS inhibitors. KRAS G12C mutants still depend on their GTP binding state in order to be fully active. By covalently binding the switch pocket II, sotorasib and adagrasib reduce KRAS G12C-GDP availability, thus impairing transition to the KRAS-GTP active form.
